Following news of a phase 3 trial of AstraZeneca’s experimental drug (In The News 23.03.18), we are notified of a new phase 1 clinical trial being conducted at Bethesda Hospital, Maryland, for acute lymphoblastic leukemia (ALL) treatment. It will use a double-barrelled approach that targets two proteins found on the surface of the cancer cells.…
Details
UK Cancer survival rates lag behind those in the rest of Western Europe. The primary reason for this is simple; cancer diagnosis is often too late to save the patient. This lamentable state of affairs is all too frequently met with the government’s complacent anodyne response that UK cancer survival rates are rising, and more…
Details
Stage 3 trials of an experimental targeted cancer drug produced by AstraZeneca that includes a bacterial toxin shows promise in treating the most common cancer in children, B-cell acute lymphoblastic leukaemia (ALL). However, therapeutic benefits in the trial appear to be limited, because trial patients are quickly developing therapeutic resistance to the drug and relapse. A…
Details
Approximately 10–15 per cent of breast cancer tumour do not respond to treatment with standard hormone therapy, which means that they are more aggressive and often recur. An international research team led by Professor Kristian Pietras at Lund University, Sweden, has uncovered a way to treat these aggressive tumours through manipulation of the connective tissue…
Details